-
Mashup Score: 2Genetic and Inflammatory Biomarkers Classify Small Intestine Inflammation in Asymptomatic First-degree Relatives of Patients With Crohn’s Disease - 5 month(s) ago
Relatives of individuals with Crohn’s disease (CD) carry CD-associated genetic variants and are often exposed to environmental factors that increase their risk for this disease. We aimed to estimate the utility of genotype, smoking status, family history, and biomarkers can calculate risk in asymptomatic first-degree relatives of patients with CD.
Source: www.cghjournal.orgCategories: General Medicine News, GastroenterologyTweet
-
Mashup Score: 4Diet-Plays-Vital-Role-in-IBD-Care - 7 month(s) ago
Food-can-have-a-direct-effect-on-inflammation-and-disease-activity-in-IBD-making-diet-and-nutrition-a-critical-component-of-disease-management-for-patients
Source: www.gastroendonews.comCategories: Gastroenterology, Latest HeadlinesTweet-
Diet and nutrition play a critical role in disease management for patients with Crohn’s and ulcerative colitis, according to @CourtSchuchmann. #IBD #Crohns #UC https://t.co/HIQUVCvzvW
-
-
Mashup Score: 0Taha Qazi, MD: Finding Upadacitinib's Role in Crohn's Disease - 9 month(s) ago
Qazi reviews the selective JAK1 inhibitor’s benefit for patients who previously failed TNF inhibitor regimen.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Watch: @tqaziMD of @ClevelandClinic discusses his colleague's review of upadacitinib for the treatment of #Crohns disease, as featured in our third issue of the quarterly gastroenterology newsletter Qazi Corner. Watch the full interview here: https://t.co/V1wvvlf2b0 https://t.co/GzkTCM415E
-
-
Mashup Score: 0
Short-term anti-TNF treatment combined with surgical closure induces long-term MRI healing more frequently than anti-TNF therapy in patients with Crohn’s perianal fistulas. These data suggest that patients with Crohn’s perianal fistula amenable for surgical closure should be counselled for this therapeutic approach.
Source: www.thelancet.comCategories: Gastroenterology, Latest HeadlinesTweet-
Important long term follow-up data from the PISA II trial (primary report here: https://t.co/TY8EaZNDig) #IBD #Crohns #GITwitter https://t.co/kLvChzU6v4
-
-
Mashup Score: 0Patients with Crohn's Disease Report Low Calcium, Magnesium Intake - 9 month(s) ago
A study from China suggests calcium and magnesium malnutrition is associated with Crohn’s disease inflammation and activity.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
International research suggests patients with #Crohns often have lower levels of calcium and magnesium. Why such levels could serve as both biomarkers and treatment targets for patients with active disease: https://t.co/4QnHsYGR1H
-
-
Mashup Score: 4eClinicalMedicine, July 2023, Volume 61 - 9 month(s) ago
New general medicine open access journal, published by The Lancet, influencing clinical practice and health policy.
Source: www.thelancet.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
📢 5th Anniversary issue now online 🎂 featuring #COVID19, improving outcomes for First Nations mothers and babies, #AFib, #TB, #Crohns, #insomnia, and much more …all available #OpenAccess ❗️ Read more here: https://t.co/ghBkCq3rAM https://t.co/0ygdrPx5EN
-
-
Mashup Score: 2FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease - 11 month(s) ago
The oral JAK inhibitor is for adults with moderately to severely active Crohn’s disease whose condition failed to respond adequately or who can’t tolerate one or more TNF inhibitors.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproves upadacitinib, the first oral treatment for #Crohns disease. https://t.co/C2YSF48xzo
-
-
Mashup Score: 0FDA Approves Upadacitinib (Rinvoq) for Crohn's Disease - 11 month(s) ago
The oral JAK inhibitor is for adults with moderately to severely active Crohn’s disease whose condition failed to respond adequately or who can’t tolerate one or more TNF inhibitors.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
#FDAapproves JAK inhibitor upadacitinib for adults with moderately to severely active #Crohns disease whose condition failed to respond adequately or who can't tolerate one or more TNF inhibitors. https://t.co/wAnHWiQXJV
-
-
Mashup Score: 0FDA Approves Upadacitinib for Patients With Crohn's Disease - 11 month(s) ago
For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
This Just In: The #FDA has approved Upadacitinib, developed by @Abbvie, as a treatment for patients with #crohns disease. https://t.co/bDX2qMHM3D
-
-
Mashup Score: 5Eating Fruits and Vegetables Cuts Risk for Crohn's Disease - 11 month(s) ago
A large, prospective study provides data to guide clinicians who treat patients at high risk for Crohn’s disease.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
According to a prospective study, the consumption of unprocessed or minimally processed foods, particularly fruits and vegetables, can reduce the likelihood of developing #Crohns disease by 50 percent. https://t.co/mwBO2i0nKJ
-
1. Which population would be considered "high risk" for developing #Crohns disease? @IBDGEMProject @ibdgc 🚨 First Degree Relatives + F. calprotectin > 100ug/g + Polygenic risk score https://t.co/P7AuHeWk39 https://t.co/MkjM5V4yoO